- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02082639
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 Years
July 16, 2015 updated by: GlaxoSmithKline
Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix™) (GSK-580299) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) (GSK-208109) in Healthy Female Adolescents Aged 9-14 Years
The purpose of this study is to evaluate the immunogenicity and safety of two doses of GSK Biologicals' HPV-16/18 L1 VLP AS04 vaccine when co-administered with GSK Biologicals' HAV vaccine according to 0, 6 month schedule, compared to the administration of either of these vaccines alone.
The study will ascertain that the immune responses elicited to the two vaccines are not adversely impacted compared to when HPV-16/18 L1 VLP AS04 vaccine and HAV vaccine are administered alone.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
9 years to 14 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- A female between, and including, 9 and 14 years of age at the time of the first vaccination.
- Subjects' parent(s)/Legally Acceptable Representative(s) [LAR(s)] who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
- Written informed consent obtained from the parent(s)/LAR(s) of the subject and informed assent obtained from the subject, if appropriate, prior to enrollment.
- Healthy subjects as established by medical history and clinical examination before entering into the study.
- Female subjects of non-childbearing potential may be enrolled in the study.
Female subjects of childbearing potential may be enrolled in the study, if the subject:
- has practiced adequate contraception for 30 days prior to vaccination, and
- has a negative pregnancy test on the day of vaccination, and
- has agreed to continue adequate contraception during the entire treatment period and for two months after completion of the vaccination series.
Exclusion Criteria:
- Child in care.
- Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period (up to Month 12).
- Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. Inhaled and topical steroids are allowed.
- Planned administration/administration of a vaccine not foreseen by the study protocol within the period starting 30 days before and 30 days after the first dose of vaccine with the exception of routine vaccines such as meningococcal, pertussis, inactivated influenza, diphtheria/tetanus and/or diphtheria/tetanus-containing vaccines up to 8 days before the first dose of study vaccine.
- Concurrently participating in another clinical study, at any time during the study period (up to Month 12), in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product.
- Previous vaccination against HPV or planned administration of any HPV vaccine other than that foreseen by the study protocol during the study period (up to Month 12).
- Previous administration of MPL or AS04 adjuvant.
- Previous vaccination against hepatitis A or planned administration of any hepatitis A vaccine other than that foreseen by the study protocol during the study period (up to Month 12).
- Cancer or autoimmune disease under treatment.
- History of hepatitis A infection.
- Known exposure to hepatitis A within the previous 6 weeks.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
- History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines.
- Hypersensitivity to latex.
- Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests, which in the opinion of the investigator preclude administration of the study vaccine.
- Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period (up to Month 12).
Acute disease and/or fever at the time of enrollment.
- Fever is defined as temperature ≥ 37.0°C for oral, axillary or tympanic route. The preferred route for recording temperature in this study will be oral or axillary.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HPV Group
Subjects will receive two doses of HPV vaccine intramuscularly
|
2 doses intramuscularly in the deltoid muscle of the non-dominant arm
|
Experimental: HAV Group
Subjects will receive two doses of HAV vaccine intramuscularly
|
2 doses intramuscularly in the deltoid muscle of the dominant arm
|
Experimental: HPV+HAV Group
Subjects will receive two doses of both HPV and HAV vaccines intramuscularly
|
2 doses intramuscularly in the deltoid muscle of the non-dominant arm
2 doses intramuscularly in the deltoid muscle of the dominant arm
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Anti-HPV-16/18 seroconversion status in the HPV group and the HPV+HAV group
Time Frame: One month after the second dose (Month 7)
|
One month after the second dose (Month 7)
|
Anti-HPV-16/18 antibody titres in the HPV group and the HPV+HAV group
Time Frame: One month after the second dose (Month 7)
|
One month after the second dose (Month 7)
|
Anti-HAV seroconversion status in the HPV+HAV group and the HAV group
Time Frame: One month after the second dose (Month 7)
|
One month after the second dose (Month 7)
|
Anti-HAV antibody titres in the HPV+HAV group and the HAV group
Time Frame: One month after the second dose (Month 7)
|
One month after the second dose (Month 7)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Anti-HPV-16/18 seroconversion status in the HPV group and the HPV+HAV group
Time Frame: One month after the second dose (Month 7)
|
One month after the second dose (Month 7)
|
Anti-HPV-16/18 antibody titres in the HPV group and the HPV+HAV group
Time Frame: One month after the second dose (Month 7)
|
One month after the second dose (Month 7)
|
Anti-HAV seroconversion status in the HPV+HAV group and the HAV group
Time Frame: One month after the second dose (Month 7)
|
One month after the second dose (Month 7)
|
Anti-HAV antibody titres in the HPV+HAV group and the HAV group
Time Frame: One month after the second dose (Month 7)
|
One month after the second dose (Month 7)
|
Occurrence of any and Grade 3 solicited local symptoms (injection site pain, redness and swelling) in all study groups
Time Frame: During the 7-day period (Day 0-6) following each vaccination
|
During the 7-day period (Day 0-6) following each vaccination
|
Occurrence of any, Grade 3 and causally related to vaccination solicited general symptoms in all study groups
Time Frame: During the 7-day period (Day 0-6) following each vaccination
|
During the 7-day period (Day 0-6) following each vaccination
|
Occurrence of any, Grade 3 and causally related to vaccination unsolicited AEs in all study groups
Time Frame: During the 30-day period (Day 0-29) following any vaccination
|
During the 30-day period (Day 0-29) following any vaccination
|
Occurrence of any and causally related to vaccination serious adverse events (SAEs) in all groups
Time Frame: Throughout the active phase of the study (up to Month 7) and during the extended safety follow-up period (up to Month 12)
|
Throughout the active phase of the study (up to Month 7) and during the extended safety follow-up period (up to Month 12)
|
Occurrence of medically significant conditions (MSCs) in all groups
Time Frame: Throughout the active phase (up to Month 7) and during the extended safety follow-up period (up to Month 12)
|
Throughout the active phase (up to Month 7) and during the extended safety follow-up period (up to Month 12)
|
Occurrence of potential immune-mediated diseases (pIMDs) in all groups
Time Frame: Throughout the active phase (up to Month 7) and during the extended safety follow-up period (up to Month 12)
|
Throughout the active phase (up to Month 7) and during the extended safety follow-up period (up to Month 12)
|
Occurrence of pregnancies and pregnancy outcomes
Time Frame: During the entire study period (Month 0 - Month 12)
|
During the entire study period (Month 0 - Month 12)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2015
Primary Completion (Anticipated)
August 1, 2015
Study Completion (Anticipated)
November 1, 2015
Study Registration Dates
First Submitted
March 6, 2014
First Submitted That Met QC Criteria
March 6, 2014
First Posted (Estimate)
March 10, 2014
Study Record Updates
Last Update Posted (Estimate)
July 20, 2015
Last Update Submitted That Met QC Criteria
July 16, 2015
Last Verified
July 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 117099
- 2012-004378-24 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infections, Papillomavirus
-
The AlfredMerck Sharp & Dohme LLCCompletedHuman Papillomavirus Infection | Human PapillomavirusAustralia
-
University of North Carolina, Chapel HillCenters for Disease Control and Prevention; American Cancer Society, Inc.; New... and other collaboratorsWithdrawnHuman Papillomavirus InfectionUnited States
-
Merck Sharp & Dohme LLCCompletedHuman Papillomavirus Infection
-
Sanford HealthCompletedHuman Papillomavirus InfectionUnited States
-
GlaxoSmithKlineCompletedHuman Papillomavirus InfectionBahrain
-
CHU de Quebec-Universite LavalCentre hospitalier de l'Université de Montréal (CHUM); Institut National en... and other collaboratorsCompletedHuman Papillomavirus InfectionsCanada
-
Kanazawa Medical UniversityMerck Sharp & Dohme LLCUnknownPapillomavirus Infections | Papillomavirus Vaccines
-
H. Lee Moffitt Cancer Center and Research InstituteCompletedHuman Papillomavirus InfectionUnited States
-
GlaxoSmithKlineCompletedInfections, Papillomavirus | Papillomavirus VaccinesBelgium, United States
-
GlaxoSmithKlineCompletedInfections, Papillomavirus | Papillomavirus VaccinesDenmark, Poland, Lithuania
Clinical Trials on Cervarix™
-
GlaxoSmithKlineCompletedInfections, Papillomavirus | Papillomavirus VaccinesDenmark, Poland, Lithuania
-
GlaxoSmithKlineCompletedCervical Intraepithelial Neoplasia | Papillomavirus Type 16/18 InfectionEstonia
-
GlaxoSmithKlineWithdrawn
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedCervical Intraepithelial Neoplasia | Papillomavirus InfectionTaiwan, Germany, Colombia, Honduras, Panama
-
GlaxoSmithKlineCompletedInfections, PapillomavirusUnited States, Canada
-
GlaxoSmithKlineCompletedInfections, PapillomavirusCanada, Denmark, Hungary, Sweden
-
GlaxoSmithKlineCompletedInfections, PapillomavirusUnited States, Spain, Finland, Germany, Taiwan, Belgium, Philippines, Canada, Australia, United Kingdom, Thailand, Brazil, Italy, Mexico
-
GlaxoSmithKlineCompletedFollow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North AmericaInfections, PapillomavirusCanada, United States